Wells Fargo
RNAZ icon

Wells Fargo’s TransCode Therapeutics RNAZ Stock Holding History

Wells Fargo’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$342 Hold
55
– – ﹤0.01% 6548
2026
Q1 		$474 Buy
+55
New +$513 ﹤0.01% 6400
2024
Q2 		– Hold
0
– -$3 – 7368
2024
Q1 		– Hold
0
– – – 7437
2023
Q4 		– Hold
0
– – – 7127
2023
Q3 		– Hold
0
– – – 7465
2023
Q2 		– Hold
0
– – – 7466
2023
Q1 		– Hold
0
– – – 7411
2022
Q4 		– Hold
0
– – – 7126
2022
Q3 		– Hold
0
– – – 7242
2022
Q2 		– Hold
0
– – – 7367
2022
Q1 		– Hold
0
– – – 7683
2021
Q4 		– Hold
0
– – – 7704
2021
Q3 		– Hold
0
– – – 7416

Other funds holding RNAZ

YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Wells Fargo's RNAZ Position: Q2 2026 in Review

Wells Fargo held its TransCode Therapeutics (RNAZ) position steady in Q2 2026 at 55 shares worth $342. The position accounts for ﹤0.01% of the portfolio, ranked #6548.

Wells Fargo first reported a position in RNAZ in Q1 2026 and has held it in 2 quarters since. The position peaked at $474 in Q1 2026. 8 funds tracked by Wall St. Rank hold RNAZ as of Q2 2026.

  • Wells Fargo held 55 shares of TransCode Therapeutics worth $342 as of Q2 2026.
  • Wells Fargo left its TransCode Therapeutics share count unchanged in Q2 2026.
  • TransCode Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6548 holding.
  • Wells Fargo first reported a position in TransCode Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Wells Fargo's TransCode Therapeutics position peaked at $474 in Q1 2026.
  • 8 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.